Lilly’s Abemaciclib Efficacy Data At ASCO Could Hold Up To Accelerated Review

Data presented by Eli Lilly at ASCO could support accelerated approval of abemaciclib but a tolerability issue could impact its competitive position in the commercial market versus Pfizer’s Ibrance.